Integra LifeSciences
IART
201 hedge funds and large institutions have $705M invested in Integra LifeSciences in 2026 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 62 increasing their positions, 69 reducing their positions, and 33 closing their positions.
1.01% more ownership
Funds ownership: 94.96% → 95.97% (+1%)
9% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 33
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less funds holding
Funds holding: 204 → 201 (-3)
10% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 69
23% less capital invested
Capital invested by funds: $919M → $705M (-$215M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCMI
Paradigm Capital Management Inc
Albany,
New York
|
+$14.8M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$6.47M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$6.12M |
| 4 |
Millennium Management
New York
|
+$5.2M |
| 5 |
Goldman Sachs
New York
|
+$4.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
-$15.4M |
| 2 |
QCM
Quantinno Capital Management
New York
|
-$4.2M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$3.43M |
| 4 |
Morgan Stanley
New York
|
-$2.91M |
| 5 |
SG Americas Securities
New York
|
-$2.74M |
IART Hedge Fund Activity: Q1 2026 in Review
201 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q1 2026, worth a combined $705M — down 23% from $919M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new IART positions and 33 closed out — a net gain of 3 holders — while 62 added to existing stakes and 69 trimmed.
The largest buyer was Paradigm Capital Management Inc, adding an estimated $14.8M. The largest seller was J. Goldman & Co, exiting entirely with an estimated $15.4M sold.
- 201 institutional investors held Integra LifeSciences (IART) as of Q1 2026, down from 204 in Q4 2025.
- Funds reported $705M of Integra LifeSciences stock for Q1 2026, down 23% quarter-over-quarter.
- 36 funds opened new Integra LifeSciences positions in Q1 2026 and 33 closed out, a net change of +3 holders.
- The largest Integra LifeSciences buyer in Q1 2026 was Paradigm Capital Management Inc, an estimated $14.8M added.
- The largest Integra LifeSciences seller in Q1 2026 was J. Goldman & Co, an estimated $15.4M sold.
Based on aggregated 13F filings for Q1 2026.